These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

308 related articles for article (PubMed ID: 22980441)

  • 1. Phase 1 radioimmunotherapy study with lutetium 177-labeled anti-carbonic anhydrase IX monoclonal antibody girentuximab in patients with advanced renal cell carcinoma.
    Stillebroer AB; Boerman OC; Desar IM; Boers-Sonderen MJ; van Herpen CM; Langenhuijsen JF; Smith-Jones PM; Oosterwijk E; Oyen WJ; Mulders PF
    Eur Urol; 2013 Sep; 64(3):478-85. PubMed ID: 22980441
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase 2 Study of Lutetium 177-Labeled Anti-Carbonic Anhydrase IX Monoclonal Antibody Girentuximab in Patients with Advanced Renal Cell Carcinoma.
    Muselaers CH; Boers-Sonderen MJ; van Oostenbrugge TJ; Boerman OC; Desar IM; Stillebroer AB; Mulder SF; van Herpen CM; Langenhuijsen JF; Oosterwijk E; Oyen WJ; Mulders PF
    Eur Urol; 2016 May; 69(5):767-70. PubMed ID: 26706103
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dosimetric analysis of 177Lu-cG250 radioimmunotherapy in renal cell carcinoma patients: correlation with myelotoxicity and pretherapeutic absorbed dose predictions based on 111In-cG250 imaging.
    Stillebroer AB; Zegers CM; Boerman OC; Oosterwijk E; Mulders PF; O'Donoghue JA; Visser EP; Oyen WJ
    J Nucl Med; 2012 Jan; 53(1):82-9. PubMed ID: 22159179
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Optimizing lutetium 177-anti-carbonic anhydrase IX radioimmunotherapy in an intraperitoneal clear cell renal cell carcinoma xenograft model.
    Muselaers CH; Oosterwijk E; Bos DL; Oyen WJ; Mulders PF; Boerman OC
    Mol Imaging; 2014; 13():1-7. PubMed ID: 24824962
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lack of efficacy of two consecutive treatments of radioimmunotherapy with 131I-cG250 in patients with metastasized clear cell renal cell carcinoma.
    Brouwers AH; Mulders PF; de Mulder PH; van den Broek WJ; Buijs WC; Mala C; Joosten FB; Oosterwijk E; Boerman OC; Corstens FH; Oyen WJ
    J Clin Oncol; 2005 Sep; 23(27):6540-8. PubMed ID: 16170161
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Indium-111-labeled girentuximab immunoSPECT as a diagnostic tool in clear cell renal cell carcinoma.
    Muselaers CH; Boerman OC; Oosterwijk E; Langenhuijsen JF; Oyen WJ; Mulders PF
    Eur Urol; 2013 Jun; 63(6):1101-6. PubMed ID: 23453421
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A phase I multiple dose, dose escalation study of cG250 monoclonal antibody in patients with advanced renal cell carcinoma.
    Davis ID; Wiseman GA; Lee FT; Gansen DN; Hopkins W; Papenfuss AT; Liu Z; Moynihan TJ; Croghan GA; Adjei AA; Hoffman EW; Ingle JN; Old LJ; Scott AM
    Cancer Immun; 2007 Aug; 7():13. PubMed ID: 17705349
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I radioimmunotherapy of metastatic renal cell carcinoma with 131I-labeled chimeric monoclonal antibody G250.
    Steffens MG; Boerman OC; de Mulder PH; Oyen WJ; Buijs WC; Witjes JA; van den Broek WJ; Oosterwijk-Wakka JC; Debruyne FM; Corstens FH; Oosterwijk E
    Clin Cancer Res; 1999 Oct; 5(10 Suppl):3268s-3274s. PubMed ID: 10541374
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase I clinical trial with fractionated radioimmunotherapy using 131I-labeled chimeric G250 in metastatic renal cancer.
    Divgi CR; O'Donoghue JA; Welt S; O'Neel J; Finn R; Motzer RJ; Jungbluth A; Hoffman E; Ritter G; Larson SM; Old LJ
    J Nucl Med; 2004 Aug; 45(8):1412-21. PubMed ID: 15299069
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A pilot study of monoclonal antibody cG250 and low dose subcutaneous IL-2 in patients with advanced renal cell carcinoma.
    Davis ID; Liu Z; Saunders W; Lee FT; Spirkoska V; Hopkins W; Smyth FE; Chong G; Papenfuss AT; Chappell B; Poon A; Saunder TH; Hoffman EW; Old LJ; Scott AM
    Cancer Immun; 2007 Aug; 7():14. PubMed ID: 17705350
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ImmunoPET imaging of renal cell carcinoma with (124)I- and (89)Zr-labeled anti-CAIX monoclonal antibody cG250 in mice.
    Stillebroer AB; Franssen GM; Mulders PF; Oyen WJ; van Dongen GA; Laverman P; Oosterwijk E; Boerman OC
    Cancer Biother Radiopharm; 2013 Sep; 28(7):510-5. PubMed ID: 23697926
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Optimization of radioimmunotherapy of renal cell carcinoma: labeling of monoclonal antibody cG250 with 131I, 90Y, 177Lu, or 186Re.
    Brouwers AH; van Eerd JE; Frielink C; Oosterwijk E; Oyen WJ; Corstens FH; Boerman OC
    J Nucl Med; 2004 Feb; 45(2):327-37. PubMed ID: 14960657
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I/II radioimmunotherapy trial with iodine-131-labeled monoclonal antibody G250 in metastatic renal cell carcinoma.
    Divgi CR; Bander NH; Scott AM; O'Donoghue JA; Sgouros G; Welt S; Finn RD; Morrissey F; Capitelli P; Williams JM; Deland D; Nakhre A; Oosterwijk E; Gulec S; Graham MC; Larson SM; Old LJ
    Clin Cancer Res; 1998 Nov; 4(11):2729-39. PubMed ID: 9829736
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Carbonic anhydrase IX in renal cell carcinoma: implications for prognosis, diagnosis, and therapy.
    Stillebroer AB; Mulders PF; Boerman OC; Oyen WJ; Oosterwijk E
    Eur Urol; 2010 Jul; 58(1):75-83. PubMed ID: 20359812
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Positron Emission Tomography/Computed Tomography with
    Hekman MCH; Rijpkema M; Aarntzen EH; Mulder SF; Langenhuijsen JF; Oosterwijk E; Boerman OC; Oyen WJG; Mulders PFA
    Eur Urol; 2018 Sep; 74(3):257-260. PubMed ID: 29730017
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Optical Imaging of Renal Cell Carcinoma with Anti-Carbonic Anhydrase IX Monoclonal Antibody Girentuximab.
    Muselaers CH; Stillebroer AB; Rijpkema M; Franssen GM; Oosterwijk E; Mulders PF; Oyen WJ; Boerman OC
    J Nucl Med; 2014 Jun; 55(6):1035-40. PubMed ID: 24752673
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Towards effective CAIX-targeted radionuclide and checkpoint inhibition combination therapy for advanced clear cell renal cell carcinoma.
    Kleinendorst SC; Oosterwijk E; Molkenboer-Kuenen J; Frielink C; Franssen GM; Boreel DF; Tamborino G; Gloudemans M; Hendrikx M; Kroon D; Hillen J; Bussink J; Muselaers S; Mulders P; Konijnenberg MW; Wheatcroft MP; Twumasi-Boateng K; Heskamp S
    Theranostics; 2024; 14(9):3693-3707. PubMed ID: 38948062
    [No Abstract]   [Full Text] [Related]  

  • 18. Carbonic anhydrase IX expression in clear cell renal cell carcinoma and normal tissues: experiences from (radio) immunotherapy.
    Brouwers AH; Mulders PF; Oyen WJ
    J Clin Oncol; 2008 Aug; 26(22):3808-9; author reply 3811-2. PubMed ID: 18669472
    [No Abstract]   [Full Text] [Related]  

  • 19. Molecular imaging and carbonic anhydrase IX-targeted radioimmunotherapy in clear cell renal cell carcinoma.
    Muselaers S; Mulders P; Oosterwijk E; Oyen W; Boerman O
    Immunotherapy; 2013 May; 5(5):489-95. PubMed ID: 23638744
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Investigation of hypoxia and carbonic anhydrase IX expression in a renal cell carcinoma xenograft model with oxygen tension measurements and ¹²⁴I-cG250 PET/CT.
    Lawrentschuk N; Lee FT; Jones G; Rigopoulos A; Mountain A; O'Keefe G; Papenfuss AT; Bolton DM; Davis ID; Scott AM
    Urol Oncol; 2011; 29(4):411-20. PubMed ID: 19523858
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.